COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #184 of 230
11/17 Late treatment study
Boari et al, Biosci. Rep., doi:10.1042/BSR20203455 (Peer Reviewed)
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study
Source   PDF   Share   Tweet
Retrospective 258 hospitalized patients in Italy showing lower mortality with HCQ treatment, unadjusted relative risk RR 0.455, p<0.001.
(data is in the supplementary appendix)

Boari et al., 11/17/2020, retrospective, Italy, Europe, peer-reviewed, 20 authors.
risk of death, 54.5% lower, RR 0.45, p < 0.001, treatment 41 of 202 (20.3%), control 25 of 56 (44.6%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.